The Company is engaged in the research, development, manufacture and distribution of pharmaceutical products in the China.
The best Bull and Bear pitches based on recency and number of recommendations.
Since this is CAPS, I'm taking 3SBio at their word regarding their 18M quarterly revenues and expected 20-30% topline growth in 2011. In the real world, I will not likely ever invest in a company based in China again.
Read the most recent pitches from players about SSRX.DL.
Find the members with the highest scoring picks in SSRX.DL.
See what the Wall Street professionals think, according to their public statements and filings.